RxDoctor Payments Data

Kenneth Francez, MD

Interventional Cardiology · Mobile, ALNPI 1912950494

Payments from drug & device makers

$1,638in general payments, 2019–2025

Across 116 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$862
  • Johnson & Johnson$215
  • Merck$153
  • Pfizer$135
  • Amgen$66
  • Amarin Pharma, Inc.$51
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$1,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,638 in reported general payments places this provider in the 15th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$23,419
Medicare patients
61
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan39$44,971
EliquisApixaban37$31,668
XareltoRivaroxaban14$9,632
Repatha SureclickEvolocumab12$8,273
Metoprolol Succinate56$700
Ranolazine ErRanolazine12$609
Amiodarone Hcl15$453
Carvedilol48$429
Losartan Potassium34$347
Atorvastatin Calcium38$297
Lisinopril24$270
Isosorbide Mononitrate ErIsosorbide Mononitrate12$220
Amlodipine Besylate23$189
Furosemide36$183
Rosuvastatin Calcium23$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$862$44,97139 claims
PfizerEliquis$135$31,66837 claims
Johnson & JohnsonXarelto$215$9,63214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →